MDI and DPI Drug Products
...establish a set of criteria to which a drug substance or drug product should conform using.....An alternative approach may be used if such approach satisfies the requirements of the.....of each facility involved in the manufacturing of the drug substance and excipients should..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=100)
þÿ
...2 This guidance has been prepared by Drug Substance Technical Subcommittee of the Chemistry.....its specification and, therefore, can be used in the manufacture of a given drug product.....Justification for an in-process test that is used in lieu of a drug substance test should..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=82)
þÿ
...2 This guidance has been prepared by Drug Substance Technical Subcommittee of the Chemistry.....its specification and, therefore, can be used in the manufacture of a given drug product.....Justification for an in-process test that is used in lieu of a drug substance test should..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=79)
...A chemical constituent of a botanical raw material, drug substance, or drug product that is used for identification and/or quality.....These regulations require documentation of the drug substance, drug product, placebo, labeling, and an.....To ensure that a botanical drug product used in clinical trials is of consistently good quality, and..
http://www.fda.gov/cder/guidance/4592fnl.doc (score=76)
Substance
...individual batches of the drug substance used in animal and clinical testing, Drug Substance.....relation to the amount of crude product, whether it is filtered while hot, whether a.....Production of a drug substance, whether by synthesis, fermentation, or isolation, usually..
http://www.fda.gov/cder/guidance/drugsub.pdf (score=75)
GUIDE TO INSPECTIONS OF BULK PHARMACEUTICAL CHEMICALS
...Related substances are defined as those structurally related to a drug substance such as a degradation product or impurities.....a substance that is represented as a drug and, when used, becomes an active ingredient or finished dosage.....The USP also notes that the impurity profile of a drug substance is a description of the..
http://www.fda.gov/ora/inspect_ref/igs/bulk.html (score=50)
stability guidance -draft
...this guidance to mean a batch of drug substance or drug product manufactured at the scale typically encountered.....and the test methods used to monitor the stability of the drug substance and preliminary.....and the test methods used to monitor the stability of the drug product packaged in the..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=102)
Guidance- Content & Format CMC for Vaccine & Related Product
...A list should be provided of all components in the drug product, including drug substance(s)and other ingredients, with.....same areas used to produce the drug substance that is the subject of this application.....This section should contain information on the final drug product including all drug substances..
http://www.fda.gov/cber/gdlns/cmcvacc.pdf (score=88)
WAIS Document Retrieval
...Such studies should normally be conducted on the drug product or drug substance containing the degradation.....This guideline also does not address the regulation of drug products used during the clinical research.....Safety studies should provide a comparison of results of safety testing of the drug product or drug substance..
http://www.fda.gov/cder/guidance/ichq3b.htm (score=50)
Guidance for Industry Botanical Drug Products
...These regulations require documentation of the drug substance, drug product, placebo, labeling, and an.....To ensure that a botanical drug product used in clinical trials is of consistently good quality, and.....The quality control tests performed on each batch of the drug substance, the analytical procedures used, and the available test..
http://www.fda.gov/cder/guidance/4592fnl.htm (score=44)
Guidance for Industry: Human Somatic Cell Therapy and Gene Therapy
...Note that if drug substance (defined as bulk product not necessarily in final formulation)and.....Virus or DNA preparations used as preventive vaccines are not covered by this document.....abbreviate testing and IND submission for a product or product series, the sponsor should..
http://www.fda.gov/cber/gdlns/somgene.pdf (score=42)
PTC in Manufacture and Testing of Monoclonal Antibody Products for Human Use
...These trials cannot be used by themselves to support licensure of a product.Studies conducted in normal volunteers are not included in.....entity or is produced by a novel process, and when drug development plans are unusually.....Purified Bulk Lots (Drug Substance) In addition to lot-to-lot safety testing summarized in..
http://www.fda.gov/cber/gdlns/ptc_mab.pdf (score=38)
...only a limited characterization of the processes used to prepare the product for their ability to remove.....Sponsors should study a number of separate product lots during drug development to demonstrate that a safe and.....Purified Bulk Lots (Drug Substance) In addition to lot-to-lot safety testing summarized in..
http://www.fda.gov/cber/gdlns/ptc_mab.txt (score=36)
Draft Guidance for Industry: Drugs, Biologics and Medical Devices Derived...
...the purified drug substance is held prior to further processing, a description of the.....including the data from the material used to prepare clinical/pre-clinical lots and.....field trials will be obtained prior to submission of a product application, APHIS/BRS will..
http://www.fda.gov/OHRMS/DOCKETS/98fr/02d-0324-gdl0001.pdf (score=35)
Draft Guidance for Industry: Drugs, Biologics and Medical Devices Derived...
...the purified drug substance is held prior to further processing, a description of the.....including the data from the material used to prepare clinical/pre-clinical lots and.....field trials will be obtained prior to submission of a product application, APHIS/BRS will..
http://www.fda.gov/cber/gdlns/bioplant.pdf (score=35)
Content and Format of INDs for Phase 1 Studies of Drugs, Inclu
...proposed for use in a clinical study to the drug product used in the animal..toxicology studies that.....of the IND to demonstrate that the new drug substance and drug product..are within acceptable.....clinical use and the drug product used in the animal toxicology..trials that formed the basis for the..
http://www.fda.gov/cder/guidance/clin2.pdf (score=35)
IND content and format for Phase 1 studies
...As clinical development of a drug product proceeds,sponsors should discuss the manufacturing.....being proposed for use in a clinical study to the drug product used in..the animal toxicology studies.....drug substance and drug product are within acceptable chemical and..physical limits for the..
http://www.fda.gov/cder/guidance/phase1.pdf (score=33)
...Systemic exposure patterns reflect both release of the drug substance from the drug product and a series of possible.....If the drug product is to be used predominantly in the elderly, we also recommend that the sponsor attempt to.....Orally Administered Drugs Intended for Local Action Documentation of product quality BA for NDAs where the drug substance produces..
http://www.fda.gov/cder/guidance/5356fnl.doc (score=31)
ichq5c
...either drug substance or drug product should be based on long-term, real-time, real.....representative of the quality of the material used in preclinical and clinical studies and.....derived from the analytical profiles of batches of the drug substance and drug product..used in the preclinical and..
http://www.fda.gov/cder/guidance/ichq5c.pdf (score=18)
...Primary data to support a requested storage period for either drug substance or drug product should be based on.....A supplemental glossary is also included that explains certain terms used in the.....Studies of the exposure of the drug substance or drug product to extreme conditions may help to reveal patterns..
http://www.fda.gov/cber/gdlns/ichq5c071096.txt (score=15)
Powered by viXML, providing custom search results
Las Vegas Injury Lawyer
